Amicus Therapeutics, Inc

FOLD Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of FOLD by members of U.S. Congress

Politician Type Traded
Daniel S. Goldman House / D Sale $1,001 - $15,000 Apr 10, 2023
FOLD Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
FOLD Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
FOLD Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in FOLD holdings by institutional investors

Insider Trading

Quarterly net insider trading by FOLD's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $10,000 Oct 02, 2025 Issue: Health Issues
  • $10,000 Jul 01, 2025 Issue: Health Issues
  • $10,000 Apr 02, 2025 Issue: Health Issues
  • $10,000 Jan 05, 2025 Issue: Health Issues
  • $10,000 Oct 10, 2024 Issue: Health Issues
  • $10,000 Jul 02, 2024 Issue: Health Issues
  • $10,000 Apr 01, 2024 Issue: Health Issues
  • $10,000 Oct 05, 2023 Issue: Health Issues
  • $20,000 Jul 21, 2023 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
  • $10,000 Jun 30, 2023 Issue: Health Issues
  • $20,000 Jan 23, 2023 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
  • $10,000 Jan 01, 2023 Issue: Health Issues
  • $20,000 Oct 24, 2022 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
  • $10,000 Oct 04, 2022 Issue: Health Issues
  • $20,000 Jul 27, 2022 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
  • $10,000 Jul 05, 2022 Issue: Health Issues
  • $20,000 Apr 20, 2022 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
  • $10,000 Apr 04, 2022 Issue: Health Issues
  • $20,000 Jan 30, 2022 Issue: Medicare/Medicaid Health Issues Medical/Disease Research/Clinical Labs
  • $10,000 Jan 04, 2022 Issue: Health Issues
  • $20,000 Oct 27, 2021 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $10,000 Oct 01, 2021 Issue: Health Issues
  • $20,000 Jul 20, 2021 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $10,000 Jul 06, 2021 Issue: Health Issues
  • $20,000 Apr 22, 2021 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
  • $10,000 Apr 15, 2021 Issue: Health Issues
  • $10,000 Jan 05, 2021 Issue: Health Issues
  • $10,000 Oct 02, 2020 Issue: Health Issues
  • $10,000 Jul 16, 2020 Issue: Health Issues
  • $10,000 Apr 11, 2020 Issue: Health Issues
  • $10,000 Jan 13, 2020 Issue: Health Issues
  • $20,000 Jan 10, 2020 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
  • $20,000 Oct 18, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $10,000 Oct 15, 2019 Issue: Health Issues
  • $10,000 Jul 05, 2019 Issue: Health Issues
  • $10,000 Apr 17, 2019 Issue: Health Issues
  • $10,000 Jan 16, 2019 Issue: Health Issues
  • $10,000 Oct 15, 2018 Issue: Health Issues
  • $10,000 Jul 18, 2018 Issue: Health Issues
  • $10,000 Apr 10, 2018 Issue: Health Issues
  • $10,000 Jan 19, 2018 Issue: Health Issues
  • $10,000 Oct 20, 2017 Issue: Health Issues
  • $10,000 Jul 20, 2017 Issue: Health Issues
  • $10,000 Apr 21, 2017 Issue: Health Issues
  • $10,000 Jan 20, 2017 Issue: Health Issues
  • $10,000 Oct 20, 2016 Issue: Health Issues
  • $10,000 Jul 20, 2016 Issue: Health Issues
  • $10,000 Apr 19, 2016 Issue: Health Issues
  • $10,000 Jan 20, 2016 Issue: Health Issues
  • $15,000 Oct 20, 2015 Issue: Health Issues
  • $15,000 Jul 20, 2015 Issue: Health Issues
  • $10,000 Oct 15, 2010 Issue: Health Issues
  • $20,000 Jul 16, 2010 Issue: Health Issues
Corporate Lobbying

FOLD Estimated quarterly lobbying spending

Revenue Breakdown

FOLD Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
FOLD Income Statement
FOLD Balance Sheet
FOLD Cash Flow
U.S. Patents

New FOLD patent grants

  • Patent Title: Drug package Aug. 12, 2025
  • Patent Title: Drug package Jul. 08, 2025
  • Patent Title: Method to predict response to pharmacological chaperone treatment of diseases Jun. 29, 2021
  • Patent Title: Drug package Mar. 10, 2020
  • Patent Title: Drug package Nov. 19, 2019
  • Patent Title: Drug package Mar. 26, 2019
  • Patent Title: Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Jun. 19, 2018
  • Patent Title: Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy Jun. 12, 2018
  • Patent Title: Methods for treatment of fabry disease Jun. 05, 2018
  • Patent Title: Pharmacological chaperones for treating obesity Apr. 10, 2018
  • Patent Title: Method for treating cerebral amyloid angiopathy using pharmacological chaperones to increase the activity of gangliosidases Apr. 03, 2018
  • Patent Title: Chemical crosslinkers Feb. 13, 2018
  • Patent Title: Compounds and method for treating or preventing disease conditions associated with alpha-1-antitrypsin Jan. 16, 2018
  • Patent Title: Stable parenteral dnj compositions Nov. 28, 2017
  • Patent Title: Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity Nov. 21, 2017
  • Patent Title: Compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system Sep. 05, 2017
  • Patent Title: Α-galactosidase a and 1-deoxygalactonojirimycin co-formulation Jul. 04, 2017
  • Patent Title: Dosing regimens for treating and/or preventing cerebral amyloidoses Jun. 13, 2017
  • Patent Title: Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of mps iiic Mar. 21, 2017
  • Patent Title: Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes Mar. 21, 2017
  • Patent Title: Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity Feb. 14, 2017
  • Patent Title: Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases Jan. 17, 2017
  • Patent Title: Method to predict response to pharmacological chaperone treatment of diseases Jan. 17, 2017
  • Patent Title: Method for preparing isofagomine and its derivatives Nov. 01, 2016
  • Patent Title: Methods for treatment of fabry disease Nov. 01, 2016
  • Patent Title: Compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system Oct. 11, 2016
  • Patent Title: Compositions for preventing and/or treating degenerative disorders of the central nervous system Aug. 09, 2016
  • Patent Title: High concentration alpha-glucosidase compositions for the treatment of pompe disease Aug. 02, 2016
  • Patent Title: Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase Aug. 02, 2016
  • Patent Title: Pharmacological chaperones for treating obesity Jul. 05, 2016
  • Patent Title: High concentration α-glucosidase compositions for the treatment of pompe disease Apr. 05, 2016
  • Patent Title: Signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins Mar. 08, 2016
  • Patent Title: Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity Feb. 09, 2016
  • Patent Title: Utilization of pharmacological chaperones to improve manufacturing and purification of biologics Dec. 08, 2015
  • Patent Title: Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives Nov. 10, 2015
  • Patent Title: Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase Sep. 01, 2015
  • Patent Title: Method to predict response to pharmacological chaperone treatment of diseases Aug. 04, 2015
  • Patent Title: Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Jun. 16, 2015
  • Patent Title: Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases Jun. 02, 2015
  • Patent Title: Methods for treatment of fabry disease Apr. 07, 2015
  • Patent Title: Compounds and methods for treating or preventing disease conditions associated with α-1-antitrypsin Mar. 31, 2015
  • Patent Title: Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity Feb. 24, 2015
  • Patent Title: Methods for preventing and/or treating lysosomal storage disorders Jan. 27, 2015
  • Patent Title: Compositions for preventing and/or treating degenerative disorders of the central nervous system Dec. 10, 2013
  • Patent Title: Compositions for preventing and/or treating lysosomal storage disorders Dec. 10, 2013
  • Patent Title: Method to predict response to pharmacological chaperone treatment of diseases Nov. 26, 2013
  • Patent Title: Method for preparing isofagomine and its derivatives Jul. 16, 2013
  • Patent Title: Mouse model for pompe disease and methods of use thereof Jun. 18, 2013
  • Patent Title: Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers Mar. 19, 2013
  • Patent Title: Multiple compartment dosing model Nov. 27, 2012
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to FOLD from public contracts

FOLD News

Recent insights relating to FOLD

CNBC Recommendations

Recent picks made for FOLD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in FOLD

FOLD Analyst Ratings

FOLD Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
FOLD Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $FOLD stock a Buy, Sell, or Hold?

  • What is the price target for $FOLD stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

FOLD Top Shareholders
Shareholder
Shares Held
FOLD Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $FOLD stock?

  • Who owns the most shares of $FOLD stock?

  • What funds own $FOLD stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

FOLD Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view FOLD Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About FOLD

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

  • Address Princeton, NJ
  • Market Cap 3.0 billion
  • Employees 499
  • Industrial Classification Pharmaceutical Preparations
Back To Top